Acumen Pharmaceuticals Inc. Announces Amended Agreement With Merck & Co., Inc. To Include Exclusive Diagnostic Rights
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals, a leading pre-clinical biotech company working in Alzheimer’s therapeutics, today announced that it has amended its existing license agreement with Merck & Co., Inc. to grant an exclusive license to research and develop amyloid-derived diffusible ligand (ADDL) directed diagnostic products.